Navigation Links
SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO

osition: relative;">

The information in the abstracts may contain forward-looking statements including our expectations and beliefs regarding progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended," “suggested” and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including the progress or failure of clinical trials, unanticipated delays or additional expenses incurred during our clinical trials, delays in analyzing and synthesizing data obtained from clinical trials and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.


Corporate Contact
Richard A. Waldron
Executive Vice President and Chief Financial Officer
SciClone Pharmaceuticals, Inc.
650-358-3437


'"/>




Page: 1 2

Related medicine technology :

1. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SciClone Announces ZADAXIN and SCV Abstracts Accepted ASCO
(Date:8/4/2015)... IRVINE, Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... announced financial results for the three month period ended June ... Recent Non-GAAP 1 Highlights: , ... constant currency. , North American product sales grew 45% ... in constant currency, including 14% product growth in the EMEA ...
(Date:8/3/2015)...   The Intellectual Property and Science business ... of intelligent information for businesses and professionals announced ... R&D Factbook , the biopharmaceutical industry,s leading resource ... in R&D, the analysis identifies a surge in ... forecasts sales to reach $1.3 trillion by 2018. ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
...  China Medicine Corporation (OTC Bulletin Board: ... and distributor of Western pharmaceuticals, traditional Chinese medicines ... Republic of China, today announced that the Company ... Ministry of Agriculture ("MOA") for the Company,s proprietary ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners , ... NCV testing, announced their collegiate division, Wimbledon U , continues to not ... program at a time. , “Wimbledon U welcomes the eight new ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 ... Cancer Symposium, showed that// postmenopausal women with hormone ... years of tamoxifen were 56% less likely to ... who received placebo (P=0.004). ,“Aromasin provided ...
... in occupational settings and in the environment has been ... Journal of Occupational and Environmental Medicine, official publication of ... is a special issue providing updates on particles and ... types of studies for some particles in terms of ...
... soy-based substance. A US based study finds: BBIC improves ... multiple// sclerosis. ,A group of animals with ... animals also suffering from the same disease received a ... to walk, while those that didn't get the drug ...
... the Bombay Hospital and three other firms are planning to ... ,The Jaipur Development Authority would allot land for the five ... a Rs.2 billion Medi-City to be built here in three ... ,The state plans to be strict with the investors ...
... In the absence of vaccine against HIV/AIDS, the 'social vaccine' ... of the deadly virus, a top UN official here said ... to fight against the HIV/AIDS," said Peter Piot, executive director ... vaccine I mean to create a mass awareness to educate ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Inhaled Particles Increases the Risk of Lung Cancer 2
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
Richardson Retractor...
... The word cohesive is a new term being used ... to the more liquid fill that may have been ... is not new science, this is not new technology ... today to describe the sticking together nature of the ...
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
Medicine Products: